Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycaemic" glucose without numerically changing the incretin effect in patients with type 2 diabetes

被引：0

作者：

Foley, J. E. ^{[1
]}

Becker, L. ^{[2
]}

Koethe, L. ^{[2
]}

Dejager, S. ^{[3
]}

Schweizer, A. ^{[4
]}

Nauck, M. A. ^{[2
]}

机构：

[1] Novartis, E Hanover, NJ USA

[2] Diabet Zentrum, Bad Lauterberg Im Harz, Germany

[3] Novartis, Paris, France

[4] Novartis, Basel, Switzerland

来源：

DIABETOLOGIA | 2008年 / 51卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

917

引用

页码：S367 / S367

页数：1

共 50 条

[21] Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
Kang, Yu Mi
Jung, Chang Hee
Lee, Seung-Hwan
Kim, Sang-Wook
Song, Kee-Ho
Kim, Sin Gon
Kim, Jae Hyeon
Cho, Young Min
Park, Tae Sun
Ku, Bon Jeong
Koh, Gwanpyo
Kim, Dol Mi
Lee, Byung-Wan
Park, Joong-Yeol
DIABETES & METABOLISM JOURNAL, 2019, 43 (04) : 432 - 446
[22] The Effect of DPP-4 Inhibitor, Alogliptin, on Bone Metabolism in Patients With Type 2 Diabetes Mellitus
Yamauchi, Yuichiro
Tunekawa, Shin
Seino, Yusuke
Uenishi, Eita
Okawa, Tetuji
Fujiya, Atushi
Ishikawa, Kouta
Ogata, Hidetada
Iida, Atushi
Banno, Ryoichi
Arima, Hiroshi
Hamada, Yoji
Oiso, Yutaka
DIABETES, 2013, 62 : A276 - A277
[23] Effect of the DPP-4 inhibitor vildagliptin on fasting plasma levels of intact GLP-1 and GIP in type 1 or type 2 diabetes
Ligueros-Saylan, M.
Kelley, D. E.
He, Y. -L.
Watson, C. A.
Serra, D.
Dunning, B. E.
Deacon, C. F.
Holst, J. J.
Foley, J. E.
DIABETOLOGIA, 2006, 49 : 406 - 407
[24] Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
Aaboe, K.
Knop, F. K.
Vilsboll, T.
Deacon, C. F.
Holst, J. J.
Madsbad, S.
Krarup, T.
DIABETES OBESITY & METABOLISM, 2010, 12 (04): : 323 - 333
[25] The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes
Woerle, Hans Juergen
Carneiro, Lucianno
Derani, Ayman
Goeke, Burkhard
Schirra, Joerg
DIABETES, 2012, 61 (09) : 2349 - 2358
[26] Efficacy and tolerability of the DPP-4 inhibitor vildagliptin in drug naive patients with Type 2 diabetes aged 65 years and older.
Baron, M. A.
Schweizer, A.
Couturier, A.
Dejager, S.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (04) : S25 - S26
[27] Efficacy of Concomitant Therapy in Japanese Type 2 Diabetes Mellitus Patients With Insulin and Sitagliptin, a DPP-4 Inhibitor
Nakagami, Tomoko
Ide, Risa
Iwasaki, Naoko
Ogata, Makiko
Oya, Junko
Osawa, Mari
Tanaka, Nobue
Takaike, Hiroko
Sato, Asako
Miura, Junnosuke
Uchigata, Yasuko
DIABETES, 2013, 62 : A298 - A298
[28] Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes
Nauck, MA
El-Ouaghlidi, A
Gabrys, B
Hücking, K
Holst, JJ
Deacon, CF
Gallwitz, B
Schmidt, WE
Meier, JJ
REGULATORY PEPTIDES, 2004, 122 (03) : 209 - 217
[29] INCRETIN SENSITIVITY AND RESPONSE DURING ORAL GLUCOSE TOLERANCE TEST IN TYPE 2 DIABETES ASSESSED BY MATHEMATICAL MODELING OF THE INCRETIN EFFECT
Tura, A.
Bagger, J. I.
Ferrannini, E.
Holst, J. J.
Knop, F. K.
Vilsboll, T.
Mari, A.
DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A99 - A99
[30] Sitagliptin, a Selective DPP-4 Inhibitor, Improves Glycemic Control When-Added to Insulin, with or without Metformin, in Patients with Type 2 Diabetes
Vilsboll, Tina
Rosenstock, Julio M.
Yki-Jaervinen, Hannele
Cefalu, William T.
Chen, Yu
Ling, Yan
Meehan, Alan G.
Katz, Leonid
Engel, Samuel S.
Kaufman, Keith D.
Amatruda, John M.
DIABETES, 2009, 58 : A158 - A159

← 1 2 3 4 5 →